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Community-acquired pneumonia (CAP) is a common 
cause of intensive care unit admission and can lead to 
acute respiratory distress syndrome (ARDS) and multiple 
organ dysfunction syndrome (MODS), major causes of 
mortality after CAP. At present, treatment is supportive, 
and determining which patients will have a higher likeli-
hood of disease severity is not possible. In the previous 
issue of Critical Care, García-Laorden and colleagues [1] 
attempted to begin to unravel the complex gene-environ-
ment interactions in a syndrome whose progression is 
felt to be multifactorial. Th  e authors should be com-
mended for this work. Determining who is more likely or 
less likely to develop CAP, develop ARDS and MODS 
after CAP, or die from this infection is an important 
endeavor. Innate immunity clearly plays an important 
role. Abnormalities in the ﬁ  rst step of host defense may 
severely compromise subsequent steps of successfully 
combating infections. Th  e hope is that novel therapies 
can target these most susceptible patients, even before 
the downstream clinical events fully develop. However, 
before this next step may be taken, certain limitations of 
the present study require further work. Of paramount 
importance is whether the results of this study are 
generalizable to populations other than a relatively 
homo  geneous Spanish Caucasoid group. Before studies 
such as the present one can be universally accepted, they 
require validation in a distinct group of individuals.
Th  e authors reported genetic associations between 
single-nucleotide polymorphisms of the surfactant 
proteins, as well as haplotypes encompassing these genes, 
with susceptibility, severity, and outcome of CAP. Several 
associations remain signiﬁ   cant even after stringent 
multiple comparison corrections. Th  ese  ﬁ  ndings are not 
surprising, given the important role of innate immunity 
in host defense. Th   ere are a signiﬁ  cant number of studies 
in which associations of genetic variants of surfactant 
protein A (SFTPA) 1, SFTPA2, and SFPD with disease 
susceptibility have been identiﬁ  ed and these cover the 
entire life span, from birth and childhood through 
adulthood [2]. Owing to their extensive complexity, the 
SFTPA genes, in particular, provide a good model with 
which to study disease susceptibility and severity. Th  e 
extensive complexity makes it a challenge to fully 
understand and interpret any associa  tions made 
(including those in the present study) but at the same 
time provides an opportunity to learn about disease 
pathogenesis. At present, although some insight into 
mechanisms underlining diﬀ   erential regulation of the 
diﬀ  erent variants in response to various insults such as 
bacteria or oxidative stress (or both) has been gained [3-
7], this knowledge is still in the early stages and is 
insuﬃ   cient for assessing how the diﬀ  erence in SFTPA 
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phenotype or for contemplating therapeutic points of 
interventions based on SFTPA genotype.
Th   e authors clearly appreciate the dual role of SP-A, its 
ability to promote proinﬂ  ammatory processes in response 
to pathogens or other insults, and its ability, under ‘basal’ 
conditions, to suppress nuclear factor-kappa-B (NF-κB) 
activation and inﬂ  ammation. However, we would like to 
raise the point that even under ‘basal’ physiologic 
conditions (that is, in the absence of an overbearing 
pathogen load), the lung is exposed daily to hundreds of 
thousands of irritants (for example, bacteria, viruses, 
pollen, and toxins) yet the lung maintains a healthy 
status. We would like to put forward the idea that, under 
physiologic conditions, SP-A, in addition to having a 
dominant eﬀ   ect on anti-inﬂ  amma  tory  processes, 
mediates a low level of proinﬂ  ammatory processes that 
are essential for the health of the lung. Several in vitro 
studies have shown the ability of SP-A, in the absence of 
pathogens, to generate a low-level pro  inﬂ  ammatory 
response [8-16]. It is possible that the SP-A-mediated 
proinﬂ  ammatory activity (high or low levels) is ‘context-
dependent’ and reﬂ   ects the magnitude of the threat. 
Whether the mechanisms of this pro  inﬂ  ammatory 
activity at low physiologic level overlap with or are 
completely diﬀ  erent from those of the high-level activity 
generated in the presence of high-load pathogens or 
other irritants remains to be determined.
Th   e collective data, including the data from this study 
of the association of surfactant proteins with disease risk, 
beg for a better understanding of the functional and 
regulatory diﬀ  erences among common and rare SPFTA 
variants. Understanding the underlining regulatory control 
diﬀ  erences among SPFTA variants could identify points 
amenable to therapeutic intervention, which could lead 
to treatment options that are truly individualized to the 
patient’s genotype. Th   e ultimate goals, once the mecha-
nisms by which these genetic diﬀ  erences  inﬂ  uence 
outcome have been deter  mined, would most likely be to 
develop novel technolo  gies that will allow the addition of 
SP-A (or even a speciﬁ  c SP-A variant) and SP-D into 
exogenous surfac  tant preparations (similar to SP-B and 
SP-C formulations that are presently being tested) and to 
target a group of individuals based on both their etiology 
of lung disease (that is, infection) and their individual 
genotype.
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